| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $64,589,589 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23DA054309 | Improving Opioid Use Disorder Treatment Retention Outcomes Using Mindfulness in Childhood Trauma Survivors | 000 | 3 | NIH | 5/15/2025 | $187,804 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082142 | MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | 000 | 3 | NIH | 12/6/2024 | $600,292 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21ES035322 | Extent of PFAS Contamination Resulting from a Fire at a Hazardous Waste Incinerator in East Liverpool, Ohio | 000 | 2 | NIH | 5/28/2025 | $131,194 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS127974 | Predictors and Biomarkers for VCID versus Cognitive Recovery after Stroke Thrombectomy in Rural Appalachia | 000 | 3 | NIH | 5/19/2025 | $574,875 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS127974 | Predictors and Biomarkers for VCID versus Cognitive Recovery after Stroke Thrombectomy in Rural Appalachia | 000 | 3 | NIH | 5/19/2025 | $121,943 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA058933 | Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal | 000 | 3 | NIH | 4/17/2025 | $496,587 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA251663 | Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After Radiation | 000 | 5 | NIH | 3/3/2025 | $314,989 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 001 | 2 | NIH | 5/22/2025 | $40,296 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 000 | 2 | NIH | 2/17/2025 | $362,672 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P50MD019476 | UK ASCEND (Achieving Success in Community-Engaged research to elimiNate Disparities) | 000 | 2 | NIH | 2/18/2025 | $540,550 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 001 | 11 | NIH | 4/30/2025 | $351,637 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 004 | 11 | NIH | 6/10/2025 | $453,771 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 000 | 11 | NIH | 2/24/2025 | $288,205 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL168085 | Development of a Percutaneous Double Lumen Cannula-Based Cavopulmonary Assist System Toward Clinical Application | 000 | 2 | NIH | 2/25/2025 | $596,904 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R24OD010435 | Research Resources for Model Amphibians | 000 | 23 | NIH | 2/14/2025 | $406,029 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK113625 | Contributions of Hepatic and Intestinal Pathways to Cholesterol Excretion | 002 | 8 | NIH | 4/15/2025 | $491,578 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 001 | 2 | NIH | 6/17/2025 | $52,982 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 000 | 2 | NIH | 3/6/2025 | $596,055 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA301113 | Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer | 000 | 1 | NIH | 2/27/2025 | $192,610 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA251478 | Local Flavor Policies to Enhance Equity in Tobacco | 001 | 5 | NIH | 5/23/2025 | $47,877 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA251478 | Local Flavor Policies to Enhance Equity in Tobacco | 000 | 5 | NIH | 4/4/2025 | $430,896 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23MH126211 | A Precision Medicine Approach to Target Engagement for Emotion Regulation | 000 | 4 | NIH | 1/27/2025 | $110,027 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 001 | 4 | NIH | 5/22/2025 | $24,899 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 000 | 4 | NIH | 2/14/2025 | $224,101 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 000 | 1 | NIH | 1/27/2025 | $458,907 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL171111 | Functional Interactions Between Lipoproteins and Protease Inhibitors in Atherosclerosis | 001 | 2 | NIH | 6/26/2025 | $65,490 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL171111 | Functional Interactions Between Lipoproteins and Protease Inhibitors in Atherosclerosis | 000 | 2 | NIH | 4/21/2025 | $589,400 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG079506 | Investigating Enlarged Perivascular Spaces as a Neuroimaging Biomarker of Cerebral Small Vessel Disease | 000 | 3 | NIH | 4/24/2025 | $40,487 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG079506 | Investigating Enlarged Perivascular Spaces as a Neuroimaging Biomarker of Cerebral Small Vessel Disease | 001 | 3 | NIH | 6/23/2025 | $282 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM155281 | Cellular and Molecular Determinants of Post-Burn Myopathy | 000 | 2 | NIH | 5/20/2025 | $368,964 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | U01DK135111 | Restoration of Impaired Awareness of Hypoglycemia U01 Consortium: University of Kentucky | 001 | 3 | NIH | 4/10/2025 | $530,098 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA060632 | Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study | 000 | 1 | NIH | 4/9/2025 | $634,048 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES033767 | Phthalate-Induced Dysregulation of Prostaglandin and Angiogenic Function During Ovulation in Women | 000 | 4 | NIH | 11/5/2024 | $442,197 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL172813 | Circadian Regulation of Cardiac Electrophysiology | 000 | 2 | NIH | 4/2/2025 | $614,817 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UH3DE032621 | Empowering dentists to reduce opioid prescriptions to young people | 001 | 3 | NIH | 5/9/2025 | $105,239 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UH3DE032621 | Empowering dentists to reduce opioid prescriptions to young people | 000 | 3 | NIH | 12/12/2024 | $947,152 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL166225 | Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis | 000 | 3 | NIH | 12/9/2024 | $598,473 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K08DK124566 | Muscle bone interaction and its role in diabetic bone disease of Type I diabetes | 000 | 5 | NIH | 12/20/2024 | $164,517 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG066724 | Novel gastrocnemius muscle characteristics in peripheral artery disease patients associated with impaired functional performance | 001 | 5 | NIH | 11/28/2024 | $272,549 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P01AG078116 | Strategies for targeting astrocyte reactivity in Alzheimer's disease and related dementias | 001 | 4 | NIH | 5/27/2025 | $3,958,139 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P01AG078116 | Strategies for targeting astrocyte reactivity in Alzheimer's disease and related dementias | 000 | 3 | NIH | 3/14/2025 | $230,000 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA282254 | Integrative Targeted Therapy for Melanoma | 001 | 2 | NIH | 5/22/2025 | $60,862 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA282254 | Integrative Targeted Therapy for Melanoma | 000 | 2 | NIH | 3/14/2025 | $547,758 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA285253 | Novel Strategy to Augmenting Immunotherapy against Melanoma | 001 | 2 | NIH | 5/23/2025 | $21,300 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070952 | Dynamic GABA and Glutamate Neurotransmission in Alzheimer’s Disease and Aging | 001 | 3 | NIH | 6/13/2025 | $53,050 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070952 | Dynamic GABA and Glutamate Neurotransmission in Alzheimer’s Disease and Aging | 000 | 3 | NIH | 3/4/2025 | $596,811 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA285253 | Novel Strategy to Augmenting Immunotherapy against Melanoma | 000 | 2 | NIH | 3/14/2025 | $191,693 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS136272 | Harnessing engineered drug-free polymeric nanoformulations to reprogram innate immune cells for spinal trauma | 000 | 2 | NIH | 2/20/2025 | $293,936 |
| | 2025 | 2025 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140148 | Role of Hypothalamic Adgrl1 in Counteracting Hypoglycemia | 000 | 1 | NIH | 6/16/2025 | $538,354 |
|
